An interventional study of Tran canula and augmented irrigation in Glaucoma, Open Angle, Pseudo-exfoliative and Cataract, sponsored by Hôpital Privé de la Baie. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Hôpital Privé de la Baie · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.
Among the 54 studies in Glaucoma with a site in France, this one is the 22nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 29 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 51st registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:
Hôpital Privé de la Baie · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Hôpital Privé de la Baie · Sites in France
Ages 18–80
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Sites in France
Ages 18–80 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is close to the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 105 across the 38 interventional studies, 120 across the 16 observational. Of the 36 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
Hôpital Privé de la Baie is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Hôpital Privé de la Baie has 4 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06274593Nantes University HospitalStudy of OCT Peripapillary Angiography in Patients With Advanced Glaucoma | 2027-04-27 |
| NCT07802769University Hospital, BordeauxMagnetic Resonance Imaging of Cerebral Connectivity and Volume in Neurodegeneration and Glaucoma | 2027-05 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07303257Hospices Civils de LyonQuality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Glaucoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pseudoexfoliative glaucoma is a glaucoma secondary to pseudoexfoliative syndrome; cataract surgery is often more difficult, with more complications. Tran's cannula is a single-use irrigation system designed for cleaning, with the pseudoexfoliative material remaining in the trabecular meshwork.
The main objective of this study is to evaluate the efficacy of the Tran cannula, in comparison with increased irrigation, in lowering intraocular pressure (IOP) in patients with pseudoexfoliative glaucoma and treated for glaucoma, and with an indication for isolated cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with Tran cannula
Procedure: Tran canula
Patients treated with augmented irrigation cannula.
Procedure: augmented irrigation
After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.
Intraocular pressure measure
Time frame: day 1, day 30, month 3, month 6 and month 12 after surgery
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2028, 31 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 31 months is close to that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Privé de la Baie